Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Infliximab och intravenös immunglobulinterapi vid behandling av patienter med steroid-refraktär lunginflammation

5 september 2026 uppdaterad av: ECOG-ACRIN Cancer Research Group

Optimera immunsuppression för steroidrefraktär anti-PD-1/PD-L1-lunginflammation

This phase II trial studies how well infliximab and intravenous immunoglobulin therapy work in treating patients with pneumonitis that does not respond to steroid treatment. Immunotherapy with monoclonal antibodies such as, infliximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Intravenous immunoglobulin therapy may improve pneumonitis. It is not yet known whether giving infliximab and intravenous immunoglobulin therapy will work better in treating patients with pneumonitis.

Studieöversikt

Detaljerad beskrivning

PRIMARY OBJECTIVE:

I. To assess pneumonitis response to additional immunosuppression (infliximab or intravenous immunoglobulin therapy [IVIG]) in patients with steroid-refractory pneumonitis at 28-days.

SECONDARY OBJECTIVES:

I. To assess functional parameters of steroid-refractory pneumonitis at day 1, 14-days and 28-days after day 1 of receipt of additional immunosuppression (infliximab or IVIG).

II. To assess radiologic parameters of steroid-refractory pneumonitis at day 1, 14-days and 28-days after day 1 of receipt of additional immunosuppression (infliximab or IVIG).

III. To assess patient-reported outcomes of steroid-refractory pneumonitis at day 1, 14-days and 28-days after day 1 of receipt of additional immunosuppression (infliximab or IVIG).

IV. To assess death after additional immunosuppression. V. To assess the rate of infections in the 28-day period after additional immunosuppression.

EXPLORATORY OBJECTIVES:

I. To examine lung tissue, bronchoalveolar lavage (BAL) and serial blood samples in patients who develop steroid-refractory pneumonitis.

II. To examine associations between BAL phenotypes and pneumonitis response, functional and radiologic parameters of pneumonitis.

III. To evaluate associations between pneumonitis and autoantibodies, T-cell expansion, and baseline cytokines in the blood.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients receive infliximab intravenously (IV) on day 1 followed by prednisone taper IV or orally (PO) for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients may receive an additional dose of infliximab IV on day 14 at the discretion of the treating physician.

ARM B: Patients receive intravenous immunoglobulin therapy IV over 2-5 days per institutional guidelines followed by prednisone taper IV or PO for 4-6 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 28, 42 and 56 days.

Studietyp

Interventionell

Inskrivning (Faktisk)

1

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Illinois
      • Chicago, Illinois, Förenta staterna, 60611
        • Northwestern University
    • Maryland
      • Baltimore, Maryland, Förenta staterna, 21287
        • Johns Hopkins University/Sidney Kimmel Cancer Center
    • Michigan
      • Battle Creek, Michigan, Förenta staterna, 49017
        • Bronson Battle Creek
      • Grand Rapids, Michigan, Förenta staterna, 49503
        • Spectrum Health at Butterworth Campus
      • Grand Rapids, Michigan, Förenta staterna, 49503
        • Mercy Health Saint Mary's
      • Kalamazoo, Michigan, Förenta staterna, 49007
        • West Michigan Cancer Center
      • Muskegon, Michigan, Förenta staterna, 49444
        • Mercy Health Mercy Campus
      • Niles, Michigan, Förenta staterna, 49120
        • Lakeland Hospital Niles
      • Norton Shores, Michigan, Förenta staterna, 49444
        • Cancer and Hematology Centers of Western Michigan - Norton Shores
      • Reed City, Michigan, Förenta staterna, 49677
        • Spectrum Health Reed City Hospital
      • Saint Joseph, Michigan, Förenta staterna, 49085
        • Lakeland Medical Center Saint Joseph
      • Saint Joseph, Michigan, Förenta staterna, 49085
        • Marie Yeager Cancer Center
      • Traverse City, Michigan, Förenta staterna, 49684
        • Munson Medical Center
      • Wyoming, Michigan, Förenta staterna, 49519
        • Metro Health Hospital
    • New York
      • New York, New York, Förenta staterna, 10065
        • Memorial Sloan Kettering Cancer Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Förenta staterna, 19111
        • Fox Chase Cancer Center
    • Virginia
      • Richmond, Virginia, Förenta staterna, 23235
        • VCU Massey Cancer Center at Stony Point
      • Richmond, Virginia, Förenta staterna, 23298
        • Virginia Commonwealth University/Massey Cancer Center

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Patients must be English-speaking and be able to provide informed consent

  • Patient must be willing and able to undergo arterial blood gas assessment as per the treating investigator. Patient must not have contraindication for arterial blood gas assessment

  • Women must not be pregnant or breast-feeding due to the potential risk to the fetus of infliximab or IVIG. All females of childbearing potential must have a blood test or urine test within 14 days prior to randomization to rule out pregnancy. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).

  • Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method(s) of contraception or to abstain from sexual intercourse for a minimum of 56 days (the duration of their participation in the study)

  • Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3

  • Patient may have received any number of lines of prior systemic therapy

  • Patient may have any solid tumor or hematologic malignancy is eligible

  • Patient must have received treatment with an anti-PD-1/PD-L1 agent either alone or in combination with another anti-cancer agent, as their most recent therapy prior to development of pneumonitis

  • Patient must have steroid-refractory pneumonitis defined as:

    • Grade 2 pneumonitis that has not clinically improved by a Common Terminology Criteria for Adverse Events (CTCAE) grade in greater than 72 hours or maximum of 14 days or
    • Grade 3 or higher pneumonitis that has not clinically improved by a CTCAE grade in greater than 48 hours or maximum of 14 days with high dose corticosteroids (methylprednisolone or prednisone 1-4 mg/kg/equivalent) as their most recent treatment for pneumonitis, as determined by the treating investigator
  • Patient may have received anti-PD-1/PD-L1 therapy as standard-of-care or part of a clinical trial

  • Patient must have had pathogen-negative infectious diagnostic evaluation within 14 days prior to randomization, and at a minimum these should include: blood culture, urine culture, sputum culture, and viral panel: rapid flu, respiratory syncytial virus (RSV), herpes simplex virus (HSV). Empiric antibiotics for culture negative infections are not an exclusion for study entry

  • Patient must have had a pathogen-negative bronchoscopic assessment of BAL fluid within 14 days prior to randomization. A minimum assessment for pathogens on BAL must include: gram stain, fungal panel, viral panel

  • Patient must have a negative tuberculosis assessment (TB spot test, quantiferon gold or tuberculin skin test) within 14 days prior to randomization

  • Patient must have chest computed tomography (CT) scan without contrast performed =< 14 days before randomization. Patient must not have a contraindication for CT

Exclusion Criteria:

  • Patient must not have clinical evidence of cardiac dysfunction (as determined by the treating investigator) as an alternative diagnosis to steroid-refractory pneumonitis
  • Patient must not be receiving anti-PD-1/-PD-L1 agent in combination with any of the following anti-cancer agents: docetaxel, cyclophosphamide, gefitinib, erlotinib, osimertinib, crizotinib, bleomycin, afatinib
  • Patient must not be receiving concurrent radiation therapy to the chest
  • Patient must not be deemed to have radiation pneumonitis. Patients with a history of stable radiation pneumonitis not requiring corticosteroid therapy within the last 3 months prior to randomization will be allowed on study
  • Patient must not have pre-existing interstitial lung disease or pneumonitis requiring corticosteroid therapy from any other cause, as determined by the treating investigator
  • Patient must not have an absolute contraindication to IVIG or infliximab, including: clinical history of severe hypersensitivity reaction, selective IgA deficiency, active hepatitis B, active tuberculosis, active human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) where a study subject has a CD4 count of =< 200 at screening, or drug interaction

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Arm A (infliximab)

Patients receive infliximab IV on day 1 followed by prednisone taper IV or PO for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients may receive an additional dose of infliximab IV on day 14 at the discretion of the treating physician.

Given IV

Andra namn:
  • Remicade

Given IV or PO

Andra namn:
  • Deltasone
  • Orasone
  • Meticorten
  • Panasol-S
  • Liquid-Pred

Given IV or PO

Andra namn:
  • Metylprednisolon (Medrol)
  • Metylprednisolonnatriumsuccinat (Solu-Medrol)
  • metylprednisolonacetat (Depo-Medrol)
Experimentell: Arm B (intravenous immunoglobulin therapy)

Patients receive intravenous immunoglobulin therapy IV over 2-5 days per institutional guidelines followed by prednisone taper IV or PO for 4-6 weeks in the absence of disease progression or unacceptable toxicity.

Given IV or PO

Andra namn:
  • Deltasone
  • Orasone
  • Meticorten
  • Panasol-S
  • Liquid-Pred

Given IV or PO

Andra namn:
  • Metylprednisolon (Medrol)
  • Metylprednisolonnatriumsuccinat (Solu-Medrol)
  • metylprednisolonacetat (Depo-Medrol)

Given IV

Andra namn:
  • IVIG
  • Intravenöst immunglobulin
  • Gammaglobulin
  • Gamma Globulin terapi
  • Immunglobulin
  • Immunglobulinterapi

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Pneumonitis Response Rate
Tidsram: At day 28

Pneumonitis response will be defined as an improvement in partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) of >= 20% measured by PaO2 and recording of the FiO2 received by the patient at the time of the arterial blood gas assessment, on day 28 compared with day 1.

At day 28

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Proportion of Patients With Radiologic Response for Steroid-refractory Pneumonitis
Tidsram: At days 1, 14, and 28

Radiologic features of steroid-refractory pneumonitis will be assessed by percentage lung parenchyma involved, percentage of ground-glass opacity in lung parenchyma, and lung volume on computed tomography. The pneumonitis and lung volume will be graded "Definitely decreased", "Probably decreased", "No significant change", "Probably increased" and "Definitely increased". Response to study therapy will be defined by combining the categories "Definitely decreased" and "Probably decreased".

At days 1, 14, and 28
Functional Parameters of Steroid-refractory Pneumonitis by Spirometry
Tidsram: At days 1, 14, and 28

Functional features of pneumonitis will be assessed by spirometry (forced vital capacity, forced expiratory volume in one second). These quantitative measures will be reported descriptively (by median, mean, and range) by timepoints and treatment arms.

At days 1, 14, and 28
Functional Parameters of Steroid-refractory Pneumonitis by Diffusion Capacity
Tidsram: At days 1, 14, and 28

Functional features of pneumonitis will be assessed by diffusion capacity of the lung. These quantitative measures will be reported descriptively (by median, mean, and range) by timepoints and treatment arms.

At days 1, 14, and 28
Functional Parameters of Steroid-refractory Pneumonitis by Oxygen Saturation
Tidsram: At days 1, 14, and 28

Functional features of pneumonitis will be assessed by oxygen saturation on room air at rest, collected as part of the vital signs. These quantitative measures will be reported descriptively (by median, mean, and range) by timepoints and treatment arms.

At days 1, 14, and 28
Number of Deaths Within 28 Days
Tidsram: Up to 28 days

Death reported in the 28-day period will be tabulated by treatment arm, and classified as pneumonitis-related, immunosuppression related, disease-related or other.

Up to 28 days
Incidence of Adverse Events
Tidsram: Up to 28 days

Will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The number and severity of treatment-related adverse events from infections in any organ system by the CTCAE reported in the 28-day period after additional immunosuppression.

Up to 28 days
Total Score of Functional Assessment of Cancer Therapy - Lung Version 4
Tidsram: At days 1, 14, and 28

Patient-reported outcomes of steroid-refractory pneumonitis will be measured by questionnaires (Functional Assessment of Cancer Therapy - Lung version 4 [FACT-L]). FACT-L consists of 5 subscales and the total score is calculated by summing the scores of the 36 items. The score ranges between 0 and 136. The higher the score, the better the quality of life.

At days 1, 14, and 28

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Distribution of Biomarkers in Patients Who Develop Steroid-refractory Pneumonitis
Tidsram: Days 1, 14 and 28 after study treatment

Potential blood/serum biomarkers for pneumonitis will be assessed from serially collected blood/serum in accrued patients (on Days 1, 14 and 28 after study treatment) and controls, whose blood/serum will be obtained as part of a parallel tissue-collection protocol.

Days 1, 14 and 28 after study treatment
To Evaluate Associations Between Pneumonitis and Autoantibodies, T Cell Expansion, and Baseline Cytokines in the Blood
Tidsram: On days 1, 14, and 28 post-treatment

To evaluate associations between pneumonitis and autoantibodies, T cell expansion, and baseline cytokines in the blood.

On days 1, 14, and 28 post-treatment

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Jarushka Naidoo, ECOG-ACRIN Cancer Research Group

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

7 januari 2021

Primärt slutförande (Faktisk)

21 december 2023

Avslutad studie (Faktisk)

26 maj 2026

Studieregistreringsdatum

Först inskickad

9 juni 2020

Först inskickad som uppfyllde QC-kriterierna

16 juni 2020

Första postat (Faktisk)

18 juni 2020

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

29 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

5 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • EAQ172
  • EAQ172 (Annan identifierare: CTEP)
  • NCI-2018-02825 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
  • UG1CA189828 (U.S.S. NIH-anslag/kontrakt)
  • EAQ172 (Annan identifierare: ECOG-ACRIN Cancer Research Group)
  • EAQ172 (Annan identifierare: DCP)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera